Harmony Biosciences Holdings, Inc. (HRMY) Income Statement
HRMY 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsHRMY revenue and net income
Where HRMY's revenue goes
2025Each bar shows an amount and its share of revenue. HRMY kept 18.3% of revenue as net income.
HRMY profit margins
HRMY growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +21.5% | +25.6% | +40.3% | — |
| Gross profit | +20.1% | +23.7% | +38.4% | — |
| Operating income | +9.2% | +20.2% | +65.1% | — |
| Net income | +9.1% | −4.4% | — | — |
| EPS (diluted) | −17.1% | +5.9% | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
HRMY quarterly EPS vs estimates
Harmony Biosciences beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 3, 2026 (estimate $1.03).
HRMY income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $868.5M | $714.7M | $582.0M | $437.9M | $305.4M | $159.7M | $6.0M | $0 |
| Cost of revenue | $198.3M | $156.8M | $121.2M | $83.5M | $55.5M | $27.7M | $1.6M | $184,000 |
| Gross profit | $670.1M | $557.9M | $460.8M | $354.4M | $249.9M | $132.0M | $4.4M | −$184,000 |
| Research & development | $189.6M | $145.8M | $76.1M | $70.9M | $30.4M | $19.4M | $69.6M | $12.4M |
| Sales, general & admin | $272.0M | $221.3M | $192.7M | $163.3M | $132.0M | $95.6M | $80.7M | $29.1M |
| Total operating expenses | $461.6M | $367.1M | $268.8M | $234.2M | $162.4M | $115.0M | $150.3M | $41.4M |
| Operating income | $208.5M | $190.8M | $192.0M | $120.2M | $87.5M | $17.0M | −$145.9M | −$41.4M |
| Interest income | $21.9M | $18.5M | $14.7M | $3.1M | $224,000 | — | — | — |
| Interest expense | $14.6M | $17.5M | $23.8M | $18.8M | $24.2M | $28.2M | $6.1M | $0 |
| Income before taxes | $215.1M | $191.8M | $173.4M | $104.7M | $37.4M | −$36.9M | −$152.0M | −$39.9M |
| Income taxes | $56.4M | $46.3M | $44.5M | −$76.8M | $2.8M | $14.9M | $6.1M | $1.5M |
| Net income | $158.7M | $145.5M | $128.9M | $181.5M | $34.6M | −$36.9M | −$152.0M | −$39.9M |
| EBITDA | $255.0M | $233.4M | $221.5M | $146.9M | $80.5M | $1.5M | −$142.7M | −$41.3M |
| EPS (diluted) | $3.35 | $4.04 | $2.84 | $2.82 | $0.83 | −$2.82 | −$2.75 | — |
| Gross margin | 77.2% | 78.1% | 79.2% | 80.9% | 81.8% | 82.6% | 73.7% | — |
| Operating margin | 24.0% | 26.7% | 33.0% | 27.4% | 28.7% | 10.6% | −2,433.8% | — |
| Net margin | 18.3% | 20.4% | 22.1% | 41.4% | 11.3% | −23.1% | −2,535.1% | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $261.3M | $215.4M | $243.8M | $239.5M | $200.5M | $184.7M | $201.3M | $186.0M | $172.8M | $154.6M | $168.4M | $160.3M |
| Cost of revenue | $63.2M | $44.5M | $68.5M | $59.6M | $38.2M | $32.0M | $54.4M | $42.8M | $32.1M | $27.5M | $43.2M | $32.3M |
| Gross profit | $198.1M | $170.9M | $175.2M | $179.8M | $162.3M | $152.7M | $146.9M | $143.3M | $140.7M | $127.1M | $125.3M | $128.0M |
| Research & development | $46.6M | $69.4M | $49.9M | $55.0M | $50.2M | $34.5M | $34.7M | $25.4M | $63.6M | $22.2M | $30.3M | $17.5M |
| Sales, general & admin | $62.2M | $64.2M | $86.7M | $59.4M | $64.0M | $62.0M | $56.5M | $56.2M | $55.7M | $52.9M | $54.8M | $46.0M |
| Total operating expenses | $108.8M | $133.6M | $136.7M | $114.3M | $114.2M | $96.5M | $91.1M | $81.5M | $119.3M | $75.1M | $85.1M | $63.5M |
| Operating income | $89.3M | $37.3M | $38.6M | $65.5M | $48.2M | $56.2M | $55.7M | $61.7M | $21.4M | $52.0M | $40.2M | $64.5M |
| Interest income | $7.1M | $5.8M | $5.9M | $5.7M | $5.3M | $5.0M | $4.5M | $4.9M | $4.7M | $4.4M | — | $4.1M |
| Interest expense | $3.1M | $3.2M | $3.5M | $3.6M | $3.6M | $3.8M | $4.2M | $4.3M | $4.4M | $4.5M | $4.8M | $7.0M |
| Income before taxes | $93.3M | $39.7M | $40.8M | $67.5M | $49.6M | $57.2M | $56.2M | $62.2M | $21.7M | $51.8M | $39.7M | $51.8M |
| Income taxes | $17.8M | $7.2M | $18.3M | $16.6M | $9.9M | $11.6M | $6.7M | $16.1M | $10.1M | $13.5M | $13.1M | $13.4M |
| Net income | $75.4M | $32.5M | $22.5M | $50.9M | $39.8M | $45.6M | $49.5M | $46.1M | $11.6M | $38.3M | $26.6M | $38.5M |
| EBITDA | $102.3M | $48.9M | $51.7M | $73.5M | $59.2M | $67.0M | $66.3M | $72.5M | $32.1M | $62.4M | $61.2M | $65.0M |
| EPS (diluted) | $1.28 | $0.79 | $0.57 | $1.08 | $0.92 | $0.78 | $1.08 | $1.03 | $1.05 | $0.88 | $0.45 | $0.97 |
| Gross margin | 75.8% | 79.3% | 71.9% | 75.1% | 81.0% | 82.7% | 73.0% | 77.0% | 81.4% | 82.2% | 74.4% | 79.8% |
| Operating margin | 34.2% | 17.3% | 15.8% | 27.3% | 24.0% | 30.4% | 27.7% | 33.2% | 12.4% | 33.7% | 23.9% | 40.3% |
| Net margin | 28.9% | 15.1% | 9.2% | 21.2% | 19.8% | 24.7% | 24.6% | 24.8% | 6.7% | 24.8% | 15.8% | 24.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in HRMY's financial statements (latest annual report filed February 24, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
HRMY financial results
In fiscal year 2025 (ended December 31, 2025), Harmony Biosciences reported revenue of $868.5 million, up 21.5% from the year before. It had net income of $158.7 million (up 9.1%), a net profit margin of 18.3%. Diluted earnings per share came to $3.35. Over five years revenue grew at an average rate of 40.3% a year.
See the HRMY stock overview for the latest quote and news, or the HRMY chart for price history and technical indicators.
HRMY income statement FAQ
What is Harmony Biosciences's annual revenue?
Harmony Biosciences reported total revenue of $868.5 million for fiscal year 2025, which ended on December 31, 2025. That was up 21.5% from $714.7 million the previous year.
Is Harmony Biosciences profitable?
Yes. Harmony Biosciences reported net income of $158.7 million in fiscal 2025, a net profit margin of 18.3%; its operating margin was 24.0%.
What is Harmony Biosciences's gross margin?
Harmony Biosciences's gross margin was 77.2% in fiscal 2025: for every $100 of revenue, Harmony Biosciences kept $77 after the direct cost of its products and services.
How much does Harmony Biosciences spend on research and development?
Harmony Biosciences spent $189.6 million on research and development in fiscal 2025, 21.8% of revenue.
How fast is Harmony Biosciences growing?
Revenue grew 40.3% a year on average over the last five fiscal years, from $159.7 million to $868.5 million.
What are Harmony Biosciences's earnings per share?
Harmony Biosciences earned $3.35 per diluted share in fiscal 2025, compared with $4.04 a year earlier.
When will Harmony Biosciences report its next earnings?
Harmony Biosciences is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 before the market opens.
When does Harmony Biosciences's fiscal year end?
Harmony Biosciences's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 24, 2026.